PASITHEA THERAPEUTICS CORP. Net Change in Cash
PASITHEA THERAPEUTICS CORP. (KTTA) reported Net Change in Cash of -$9.49 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-14
- PASITHEA THERAPEUTICS CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$4.76M.
- PASITHEA THERAPEUTICS CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$1.58M.
- PASITHEA THERAPEUTICS CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$4.32M.
- PASITHEA THERAPEUTICS CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$3.17M.
- PASITHEA THERAPEUTICS CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $48.34M.
- PASITHEA THERAPEUTICS CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$9.41M.
- PASITHEA THERAPEUTICS CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$16.76M.
- PASITHEA THERAPEUTICS CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$19.81M, a 137.58% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 8 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$9.49M 10-Q · filed 2026-08-14 | ||||||||
| 2026-03-31 | -$4.76M 10-Q · filed 2026-05-15 | ||||||||
| 2025-12-31 | $48.34M 10-K · filed 2026-03-30 | ||||||||
| 2025-09-30 | -$2.70M 10-Q · filed 2025-11-13 | ||||||||
| 2025-06-30 | $294.32K 10-Q · filed 2026-08-14 | ||||||||
| 2025-03-31 | -$1.58M 10-Q · filed 2026-05-15 | ||||||||
| 2024-12-31 | -$9.41M 10-K · filed 2026-03-30 | ||||||||
| 2024-09-30 | -$6.97M 10-Q · filed 2025-11-13 | ||||||||
| 2024-06-30 | -$8.36M 10-Q · filed 2025-08-14 | ||||||||
| 2024-03-31 | -$4.32M 10-Q · filed 2025-05-15 | ||||||||
| 2023-12-31 | -$16.76M 10-K · filed 2025-03-24 | ||||||||
| 2023-09-30 | -$13.50M 10-Q · filed 2024-11-13 | ||||||||
| 2023-06-30 | -$6.44M 10-Q · filed 2024-08-13 | ||||||||
| 2023-03-31 | -$3.17M 10-Q · filed 2024-05-14 | ||||||||
| 2022-12-31 | -$19.81M 10-K · filed 2024-03-29 | -$19.82M 10-K · filed 2023-03-30 | |||||||
| 2022-09-30 | -$10.52M 10-Q · filed 2023-11-13 | -$10.57M 10-Q · filed 2022-11-14 | |||||||
| 2022-06-30 | -$5.01M 10-Q · filed 2023-08-11 | -$5.03M 10-Q · filed 2022-08-15 | |||||||
| 2022-03-31 | -$2.68M 10-Q · filed 2023-05-12 | -$2.65M 10-Q · filed 2022-05-16 | |||||||
| 2021-12-31 | $52.72M 10-K · filed 2023-03-30 | ||||||||
| 2021-09-30 | $20.32M 10-Q · filed 2022-11-14 | ||||||||
| 2021-06-30 | $325.33K 10-Q · filed 2022-08-15 | ||||||||
| 2021-03-31 | $827.08K 10-Q · filed 2022-05-16 | ||||||||
| 2020-12-31 | $243.65K 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Rocket One Inc. (RKTO) | United States | $0.019B |